Overview
BioMed Realty is a real estate investment trust that acquires, develops, owns, and manages laboratory and office space for the life science industry, with properties in the United States and United Kingdom. It earns income by signing long-term leases with high-quality tenants such as pharmaceutical and biotechnology companies, research institutions, and government agencies, and provides ongoing property and asset management. The company differentiates itself by being one of the largest private owners and operators of life science real estate, offering specialized facilities in major innovation hubs and a stable, high-grade tenant base. Its goal is to deliver steady, long-term rental revenue while growing a premier portfolio that supports biotech and pharmaceutical ecosystems.
Work here?Claim your company
Simplify's Take
What believers are saying
- Biogen’s 585 Broadway project and TransMedics’ headquarters lease lock in long-duration cash flow.
- Babraham Research Campus fully leased its newest building in February 2026, validating UK demand.
- Gateway of Pacific won a 2026 BOMA TOBY award, strengthening tenant confidence and pricing power.
What critics are saying
- In July 2026, BioMed surrendered 1000 Washington Street and 321 Harrison Avenue to lenders.
- Boston concentration remains dangerous; one-third of BioMed’s portfolio sits in the soft South End/Cambridge market.
- If lease-up stalls again, 2027 refinancing pressure hits development-heavy campuses and blunts growth.
What makes BioMed Realty unique
- 17.3 million square feet spans Boston, Bay Area, San Diego, Seattle, Cambridge, and U.K.
- BioMed secured a 16-year, 498,000-square-foot TransMedics lease at Assembly Innovation Park in January 2026.
- BioMed’s Blackstone-backed capital base supports large, mission-critical, build-to-suit lab campuses.
Help us improve and share your feedback! Did you find this helpful?